Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma

被引：8

作者：

Andtbacka, Robert Hans Ingemar

Ross, Merrick I.

Agarwala, Sanjiv S.

Taylor, Matthew H.

Vetto, John T.

Neves, Rogerio Izar

Daud, Adil

Khong, Hung T.

Ungerleider, Richard S.

Tanaka, Maki

机构：

[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] St Lukes Hosp, Easton, PA USA

[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[5] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[6] Penn State Hershey Canc Inst, Hershey, PA USA

[7] Univ Calif San Francisco, San Francisco, CA 94143 USA

[8] Theradex, Princeton, NJ USA

[9] Takara Bio Inc, Kusatsu, Japan

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9541

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9541

引用

页数：2